Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial.
Andrzej BozekKrzysztof KołodziejczykRenata KozłowskaGiorgio Walter CanonicaPublished in: Clinical and translational allergy (2017)
This randomized, double-blinded placebo-controlled (DBPC) trial was conducted at one centre (ClinicalTrials.gov no. NCT03209245).
Keyphrases
- double blind
- placebo controlled
- phase iii
- allergic rhinitis
- phase ii
- clinical trial
- study protocol
- end stage renal disease
- phase ii study
- open label
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- middle aged
- polycyclic aromatic hydrocarbons